Neurology and Neurosurgery - Global Neurology Academy

33-48 of 498

Treating the Complex Patient: TD Management in Older Adults and Medically Fragile Populations
Treating the Complex Patient: TD Management in Older Adults and Medically Fragile Populations
MinuteCE®
Treating the Complex Patient: TD Management in Older Adults and Medically Fragile Populations
Tracy Hicks, DNP, MBA; Melissa Moody, MD
1.00 program credit
- Tracy Hicks, DNP, MBA
- Melissa Moody, MD
1.00 program credit
FXIa Remix! Keeping the Flow Without Missing a Beat
FXIa Remix! Keeping the Flow Without Missing a Beat
CME/CE
FXIa Remix! Keeping the Flow Without Missing a Beat
Mike Sharma, MD, MSc, FRCPC; Ashkan Shoamanesh, MD
0.50 credits
- Mike Sharma, MD, MSc, FRCPC
- Ashkan Shoamanesh, MD
- Brian Mac Grory, MB, BCh BAO, MRCP, FAHA, FANA
0.50 credits
Rethinking Secondary Stroke Prevention: The Emerging Role of Factor XI Inhibition
Rethinking Secondary Stroke Prevention: The Emerging Role of Factor XI Inhibition
CME/CE
Rethinking Secondary Stroke Prevention: The Emerging Role of Factor XI Inhibition
Mukul Sharma, MD, MSc, FRCPC; Ashkan Shoamanesh, MD, MSc, FRCPC
0.75 credits
- Mukul Sharma, MD, MSc, FRCPC
- Ashkan Shoamanesh, MD, MSc, FRCPC
0.75 credits
Understanding Variability in Myasthenia Gravis
Understanding Variability in Myasthenia Gravis
NeuroFrontiers
Understanding Variability in Myasthenia Gravis
Henry Kaminski, MD
- Henry Kaminski, MD
Examining the Global Genetic Prevalence of TK2d
Examining the Global Genetic Prevalence of TK2d
NeuroFrontiers
Examining the Global Genetic Prevalence of TK2d
Brian P. McDonough, MD, FAAFP; Austin Larson, MD
- Brian P. McDonough, MD, FAAFP
- Austin Larson, MD
Microglia Drive Neurodegeneration in Friedreich’s Ataxia
Microglia Drive Neurodegeneration in Friedreich’s Ataxia
NeuroFrontiers
Microglia Drive Neurodegeneration in Friedreich’s Ataxia
Ryan Quigley
- Ryan Quigley
MS in Women: How Life Stages Shape Treatment Decisions
MS in Women: How Life Stages Shape Treatment Decisions
NeuroFrontiers
MS in Women: How Life Stages Shape Treatment Decisions
Unpacking the Genetics of Friedreich’s Ataxia
Unpacking the Genetics of Friedreich’s Ataxia
NeuroFrontiers
Unpacking the Genetics of Friedreich’s Ataxia
Arnulf Koeppen, MD
- Arnulf Koeppen, MD
Friedreich’s Ataxia: Impact of Frataxin Loss
Friedreich’s Ataxia: Impact of Frataxin Loss
NeuroFrontiers
Friedreich’s Ataxia: Impact of Frataxin Loss
Arnulf Koeppen, MD
- Arnulf Koeppen, MD
Is Friedreich’s Ataxia Developmental or Degenerative?
Is Friedreich’s Ataxia Developmental or Degenerative?
NeuroFrontiers
Is Friedreich’s Ataxia Developmental or Degenerative?
Arnulf Koeppen, MD
- Arnulf Koeppen, MD
RAISE Subgroup Analysis: Zilucoplan Without Prior Rescue Therapy in gMG
RAISE Subgroup Analysis: Zilucoplan Without Prior Rescue Therapy in gMG
NeuroFrontiers
RAISE Subgroup Analysis: Zilucoplan Without Prior Rescue Therapy in gMG
Next-Generation MS Care: The Promise of Cell-Based Therapeutics
Next-Generation MS Care: The Promise of Cell-Based Therapeutics
NeuroFrontiers
Next-Generation MS Care: The Promise of Cell-Based Therapeutics
Mark Freedman, HBSc, MSc, MD, CSPQ, FAAN, FRCPC
- Mark Freedman, HBSc, MSc, MD, CSPQ, FAAN, FRCPC
BCMA mRNA CAR-T Shows Durable Benefit in MG
BCMA mRNA CAR-T Shows Durable Benefit in MG
NeuroFrontiers
BCMA mRNA CAR-T Shows Durable Benefit in MG
SPOTLIGHT Registry Findings on Eculizumab and Ravulizumab in gMG
SPOTLIGHT Registry Findings on Eculizumab and Ravulizumab in gMG
NeuroFrontiers
SPOTLIGHT Registry Findings on Eculizumab and Ravulizumab in gMG
Omaveloxolone in Friedreich’s Ataxia: Early Real-World Signals
Omaveloxolone in Friedreich’s Ataxia: Early Real-World Signals
NeuroFrontiers
Omaveloxolone in Friedreich’s Ataxia: Early Real-World Signals
FA hiPSCs in Translational Drug Development
FA hiPSCs in Translational Drug Development
NeuroFrontiers
FA hiPSCs in Translational Drug Development

3/8